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Abstract: Several studies have related pathological gambling in PD to dopamine agonist 
therapy. A mail-in survey was sent to PD patients seen at the University of Florida Move-
ment Disorders Center to determine gambling frequency and behavior, and any lifestyle or 
environmental factors associated with compulsive gambling in PD. 462 surveys were sent and 
127 completed surveys were returned, of which ten were from patients who met criteria for 
compulsive gambling. All ten were taking dopamine agonists coincident with the compulsive 
gambling. Compulsive gamblers were younger, and psychological distress measures revealed 
that compulsive gamblers exhibited higher levels of anxiety, anger, and confusion. Thus in this 
cohort, we have uncovered the several characteristics of the most likely PD compulsive gambler, 
namely: (young) age, “angry”, “anxious”, and using a (dopamine) agonist.
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Introduction
Parkinson’s disease (PD) is a progressive, degenerative neurological disorder resulting 
from the destruction of dopaminergic neurons in the substantia nigra (Samii et al 2004). 
In addition to motor dysfunction, neuropsychological deﬁ  cits in PD patients have been 
described, including deﬁ  cits in decision-making (Giovannoni et al 2000), learning 
deﬁ  cits (Swainson et al 2000), reinforcement learning (Frank et al 2004), goal-setting 
(Meiran et al 2004), and the performance of repetitive behaviors (Kurlan 2004; Samii 
et al 2004). In recent years, several studies have uncovered a subpopulation of patients 
with PD exhibiting signs of pathological gambling (Molina et al 2000; Seedat et al 
2000; Gschwandtner et al 2001; Driver-Dunkley et al 2003; Avanzi et al 2004; Kurlan 
2004; Dodd et al 2005). These studies reported that patients experienced an increased 
urge to gamble and were often unresponsive to typical treatments for pathological 
gambling, but were responsive to an adjustment in PD medications. Several studies 
have reported the onset of gambling behavior to be associated with external factors such 
as proximity of casinos and gambling facilities, and an increase in dopamine agonist 
medication, (more commonly pramipexole and ropinirole) (Molina et al 2000; Seedat 
et al 2000; Driver-Dunkley et al 2003; Dodd et al 2005) or other Parkinson’s medica-
tions (Gschwandtner et al 2001; Avanzi et al 2004). However, some studies did not 
ﬁ  nd a signiﬁ  cant correlation of pathological gambling in PD with anti-Parkinsonian 
medication (Kurlan 2004). 
To date the cause of pathological gambling in PD and the “phenotype” of the ‘at 
risk’ PD patient remain unclear. The inability of PD patients to successfully navigate 
gambling tasks could be contributing to the abnormal behavior. This supposition is 
supported by studies that have correlated dopamine levels during gambling (Bergh 
et al 1997; Shizgal and Arvanitogiannis 2003), speciﬁ  cally the fact that dopamine 
is released from the ventral striatum during the expectation of an uncertain reward Neuropsychiatric Disease and Treatment 2007:3(1) 162
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(Zald et al 2004). It is unclear whether external factors such 
as dopaminergic medication or intrinsic factors underlying 
disease progression, or a combination result in pathological 
gambling in PD. 
A survey of the patients with PD residing in North-Central 
Florida was performed to determine: gambling frequency 
and behavior; any iatrogenic and environmental factors as-
sociated with compulsive gambling in PD; and the presence 
of intrinsic factors associated with compulsive gambling in 
PD patients.
Methods
A mail-in survey was sent to all patients of the Uni-
versity of Florida Movement Disorders Center (where 
diagnosis of “probable” PD was made by a fellowship 
trained movement disorders specialist, using known cri-
teria (Hughes et al 1992)) was performed. The protocol 
was approved by the local Institutional Review Board. 
Participants were not paid for their participation. This 
survey consisted of a demographic data questionnaire 
(including age, gender, duration of PD, medications, and 
questions about lifestyle), the State-Trait Anxiety Inven-
tory (STAI), a Visual Analog Mood Scale (VAMS), the 
Neuropsychiatric Inventory, Beck’s Depression Inven-
tory-II (BDI-II), and a questionnaire on gambling and 
other compulsive behaviors (see Table 4). Items on the 
gambling survey were based on the DSM-IV criteria for 
pathological gambling and on a questionnaire provided 
by Gambler’s Anonymous. The survey was anonymous 
with an option for the participant to provide us with his 
or her name and contact information for further participa-
tion in the research.
All subjects were grouped into one of three groups: 
compulsive gamblers (CG), non-compulsive gamblers 
(NCG), and non-gamblers (NG). CG were defined as 
subjects who answered affirmatively to at least four 
of the questions on the gambling survey derived from 
the DSM-IV or Gambler’s Anonymous that indicated 
compulsive gambling behavior. NCG were defined as 
subjects who admitted to regularly engaging in gambling 
behavior, but whose responses on the gambling survey 
did not indicate compulsive gambling behavior. NG were 
defined as subjects who claimed to not engage in regular 
gambling behaviors. 
For the data analysis, frequency distributions (eg, medica-
tion status and gender) were compared using χ2 test. Most 
continuous variables (eg, age, illness duration, and most 
scores on the mood measures) were compared using analysis 
of variance (ANOVA) followed by Bonferroni post-hoc tests 
for signiﬁ  cant results. 
Results
A total of 462 surveys were mailed to PD patients in the 
North-Central Florida region, of which 182 were returned: 
127 complete and 55 incomplete surveys. Only completed 
surveys were used in the analysis of this study. Of the 127 
completed surveys, 10 (7.87%) were from PD patients who 
met criteria for CG; 27 (21.26%) PD patients were classiﬁ  ed 
as NCG; 90 (70.87%) PD patients did not engage in regular 
gambling behaviors. 
Demographic characteristics
The main characteristics of the three groups are shown in 
Table 1. The CG group was signiﬁ  cantly younger than the 
NG group (F [2,124] = 6.64, p < 0.01). The three groups 
did not differ signiﬁ  cantly in race composition, gender 
composition, or illness duration. There were more partici-
pants in CG group currently engaging in smoking behaviors 
(χ2 [2] = 23.17, p < 0.001). However, the three groups did not 
differ signiﬁ  cantly in the prevalence of alcohol use. There 
were no differences between groups in employment status 
(currently employed or retired), or stability of income source 
(ﬁ  xed or not ﬁ  xed).
Medication status
Table 2 shows medication status of the three groups. 
Compared with both the NG and the NCG groups, the CG 
group had signiﬁ  cantly more participants who were taking 
dopamine agonist medications when they were reportedly 
experiencing compulsive gambling behavior compared 
with the NG (χ2 [1] = 8.38, p < 0.005) and the NCG group 
(χ2 [1] = 4.41, p < 0.05]. The NCG and NG groups did 
not differ signiﬁ  cantly in number of participants who took 
dopamine agonist mediations [χ2 (1) = 1.76, p = 0.19]. The 
three groups did not differ signiﬁ  cantly in incident of cur-
rent treatment with levodopa, anticholinergics, amantadine, 
monoamine oxidase-B (MAO-B) inhibitors, catechol-O-
methyl transferase (COMT) inhibitors or other medications 
(see Table 2). 
Regarding the use of psychiatric medications, more 
participants in the CG group were under tricyclic anti-de-
pressant treatment compared to the NG and the NCG groups 
(χ2 [2] = 11.79, p < 0.005). The three groups did not differ 
signiﬁ  cantly in incident of current treatment of other antide-
pressants, or other psychiatric medications (see Table 2). Neuropsychiatric Disease and Treatment 2007:3(1) 163
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Personal and family psychiatric history
Statistical analysis of personal and family psychiatric 
history is listed in Table 3. There was no signiﬁ  cant differ-
ence between groups in prevalence of personal psychiatric 
diagnoses (χ2 [2] = 2.347, p = 0.31). Although a positive 
alcoholism history was more common among CG participants 
(χ2 [2] = 11.79, p < 0.005), only one person (who happened 
to be in the CG group, giving a 10% prevalence) in the entire 
cohort reported a positive alcoholism history. There was 
no signiﬁ  cant difference between groups in prevalence of 
psychiatric history in the family. 
Psychological distress measures 
The mean Beck Depression Inventory-II total score did not 
differ signiﬁ  cantly between groups. The CG group obtained 
signiﬁ  cantly higher score (representing greater degree of 
illness) on the state anxiety subscale [measuring current 
degree of anxiety] of the State-Trait Anxiety Inventory than 
the other two groups (F [2,123] = 4.30, p < 0.05). The CG 
group also demonstrated signiﬁ  cantly higher scores on the 
trait anxiety subscale (measuring pervading anxiety) of the 
State-Trait Anxiety Inventory compared with the NG group, 
but not the NCG group (F [2,119] = 3.10, p < 0.05). On the 
VAMS, the CG group obtained signiﬁ  cantly higher scores 
on the “confused” item than NG group (F [2,120] = 6.46, 
p < 0.005); there were no signiﬁ  cant differences between the 
CG and the NCG groups or the NG and the NCG groups. 
Since we did not perform objective cognitive measures in this 
study, it was difﬁ  cult to ascertain further what ‘confusion’ 
meant. In addition, the CG group demonstrated signiﬁ  cant 
higher scores on the “afraid” subscale compared to the NG 
group (F [2,119] = 3.41, p < 0.05). There were no signiﬁ  cant 
group difference between the CG and NCG groups as well 
as between the NCG and the NG groups. The CG group also 
obtained signiﬁ  cantly higher scores on the “angry” subscale 
compared to the NG and the NCG groups (F [2,120] = 5.49, 
p < 0.01). There were no signiﬁ  cant differences between 
groups on other items on the VAMS. The three groups did 
not differ signiﬁ  cantly in the status of libido.
Gambling behaviors
Several types of common gambling behaviors were included 
in the survey. The analyses showed that the CG and the 
NCG groups did not differ signiﬁ  cantly on prevalence of 
Table 1  Demographic data of all participants
   Participants 
Variable CG  NCG  NG
N   10  27  90
Age (SD)  58.7 (13.7)a  66.6 (9.1)  69.4 (8.4)
% Caucasian  100.0  100.0  92.0 
% male  80.0  81.5  58.9
Illness duration (SD)  7.8 (5.7)  10.0 (7.5)  7.8 (7.3)
Side onset
 %  right  40.0  51.9  43.7
 %  left  30.0  37.0  42.5
 %  bilateral  20.0  3.7  6.9
 %  unsure  10.0  7.4  6.9
% currently smoking   20.0b 0.0 0.0
Alcohol use
  % use daily  10.0  11.1  14.4
  % use occasionally  40.0  51.9  30.0
  % never use   50.0  37.0  55.6
% retired   88.9  77.8  86.4
% with ﬁ  xed income  90.0  81.0  81.5
Marital status
  % currently married  80.0  92.4  82.0
  % never married  0.0  3.8  1.1
 %  separated  10.0  0.0  1.1
 %  divorced  10.0  3.8  10.2
 %  widowed  0.0  0.0  5.6
Note: ap < 0.05 vs NCG and NG; bp < 0.001 vs both NCG and NG.
Abbreviations: CG, compulsive gamblers; NCG, non-compulsive gamblers; NG, non-gamblers.Neuropsychiatric Disease and Treatment 2007:3(1) 164
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Table 2  Medication data of all participants
  Participants 
Variable CG  NCG  NG
% taking dopamine agonists  100.0b,c 66.7  52.2
% taking levodopa  90.0  88.5  75.6
% taking anticholinergics   0.0  3.7  1.0
% taking amantadine  0.0  14.8  8.9
% taking MAO inhibitors  20.0  33.3  8.9
% taking comt inhibitors  0.0  11.1  21.1
% taking SSRIs  20.0  18.5  6.7
% taking tricyclics  10.0a 0.0 0.0
% taking other antidepressants  20.0  33.3  28.9
% taking anxiolytics  10.0  29.6  12.2
% taking antipsychotics  10.0  25.9  10.0
% taking other psychiatric medications  30.0  14.8  22.2
% taking other medications  0.0  7.4  4.4
Note: ap < 0.005 vs NG and NCG; bp < 0.005 vs NG; cp < 0.05 vs NCG.
Abbreviations: CG, compulsive gamblers; MAO, monoamine oxidase; NCG, non-compulsive gamblers; NG, non-gamblers; SSRI, selective serotonin reuptake inhibitor.
Table 3  Personal psychiatric history and psychiatric history in the family
  Participants 
Variable CG  NCG  NG
% any personal psychiatric history  40.0  37.0  24.4
% personal depression history (out of N)  20.0  29.6  21.1
% personal anxiety history  0.0  18.5  8.9
% personal bipolar disorder history  0.0  3.7  0.0
% personal OCD history# 10.0  0.0  1.1
% personal alcoholism history  10.0a 0.0  0.0
% with > one personal psychiatric history   0.0  30.0  22.7
(among people with any psychiatric history)     
% any family psychiatric history  30.0  33.3  36.7
% family depression history (out of N)  10.0  18.5  26.7
% family anxiety history  0.0  3.7  5.6
% family bipolar disorder history  10.0  3.7  8.9
% family OCD history  10.0  3.7  1.1
% family alcoholism history  10.0  14.8  13.3
% with > one family psychiatric history  33.3  22.2  33.3
(among people with any family psychiatric history) 
Note: ap <0.005 vs NG and NCG.
Abbreviations: CG, compulsive gamblers; NCG, non-compulsive gamblers; NG, non-gamblers OCD, obsessive-compulsive disorder.
engaging in different gambling behaviors, including state 
lottery, scratch-off tickets, slot machines, dog/horse track, 
casinos, cards (poker, blackjack, etc), and other gambling 
behaviors. In the CG group, 60% of people engaged in more 
than one gambling behavior; in the NCG group, 59.3% of 
people engaged in more than one gambling behavior. The 
most common gambling behavior in the CG group was “slot 
machines” (70%), followed by “scratch-off tickets” (50%), 
“cards” (40%), “state lottery” (30%), “casinos”(30%), and 
“dog/horse track” (20%). In the NCG group, the most com-
mon gambling behavior was “cards” (55.6%), followed by 
“state lottery” (51.9%), “slot machines” (48.1%), “scratch-off 
tickets” (33.3%), “casinos” (29.6%), and “dog/horse track” 
(11.1%). 
Discussion
Use of a dopamine agonist medication and younger age were 
signiﬁ  cant for the CG group in this study. However, this 
result may be confounded by the standard practice of using 
dopamine agonists in younger patients (Unwin et al 2000). 
Dopamine agonists are prescribed more often in younger 
patients primarily to delay the use of levodopa, and prevent 
early motor ﬂ  uctuations and dyskinesias (Destee 2005; 
Jankovic 2005; Moller et al 2005).  Neuropsychiatric Disease and Treatment 2007:3(1) 165
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Our data corroborates other studies that have linked 
compulsive gambling in PD to dopamine agonist medication 
(Molina et al 2000; Seedat et al 2000; Gschwandtner et al 
2001; Driver-Dunkley et al 2003; Avanzi et al 2004; Dodd 
et al 2005). There has been one previous study which reported 
compulsive gambling behavior in PD that was reported not to 
be related to PD medications (Kurlan 2004). However, both 
patients reported in that study were taking pramipexole, and 
while the authors stated that the patients’ gambling behavior 
did not resolve with discontinuing the medication, the authors 
failed to note the length of a washout period was employed. 
Other studies have reported that the latency of resolution 
of gambling behavior following discontinuing dopamine 
agonist medication could four or more weeks (Dodd et al 
2005). Finally, there are at least two other studies that have 
been unclear as to how long the behavior persisted follow-
ing medication discontinuation (Gschwandtner et al 2001; 
Driver-Dunkley et al 2003). 
Dopamine agonists enhance the functioning of endog-
enous dopamine, and non-speciﬁ  c action of the agonists may 
also inﬂ  uence non-motor basal ganglia loops, including the 
nucleus accumbens, mesolimbic/mesocortical circuits, and 
the anterior cingulated loop (Clarke and Guttman 2002). It 
has been theorized that dopamine agonists stimulate com-
pulsive gambling behavior by selectively stimulating the D3 
receptor, which have been shown previously to be localized 
to the limbic regions of the brain (Alexander et al 1990). 
Other studies have shown that pramipexole and ropinirole, 
the two dopamine agonists that are most often associated 
with compulsive gambling, are relatively selective for the 
D3 receptor (Dodd et al 2005). Finally, there is a literature 
suggesting that defects in the D2 dopamine receptor are linked 
to pathological gambling (Sokoloff et al 1990; Comings 
et al 1996; Noble 2000).
Gambling in this cohort was found to be more common 
among men than women, and this was consistent with the 
literature (Unwin et al 2000). Also in agreement with other 
studies, compulsive gambling among PD patients also seems 
to be more common among men—other studies have reported 
men composed 7 of 9 and 9 of 11 PD compulsive gamblers, 
respectively (Driver-Dunkley et al 2003; Dodd et al 2005). 
Contrary to previous studies on compulsive gambling in the 
general population (Levens et al 2005), neither family history 
of alcoholism nor depression was a signiﬁ  cant predictor of 
compulsive gambling behavior. This result will need to be 
conﬁ  rmed by larger and better constructed studies.
“Anxious”, “afraid”, “angry”, and “confused” were the 
four moods reported by the State-Trait Anxiety Inventory 
and VAMS found to be signiﬁ  cant for the CG group. We 
primarily used the VAMS to probe into emotions such as 
anger and anxiety. “Anxious” and “afraid” could be describ-
ing the same emotion. However, we are more comfortable 
with “anxious” because we have more anxiety scales that 
support it; indeed, a follow-up of this study involves the 
Table 4  Scores on psychological distress measures
 Participants 
 CG  NCG  NG
Measure M  (SD)  M  (SD)  M  (SD)
Beck Depression Inventory-II  16.1   (8.0)  9.9   (5.8)  11.7  (8.6)
State-Trait Anxiety Inventory                
State anxiety   46.4a  (10.6)  35.3   (10.8)  35.1   (11.9)
Trait anxiety   45.3b  (12.0)  36.0   (11.0)  35.5   (12.0)
Visual Analog Mood Scale               
Afraid (T score)  65.2b  (15.5)  54.1   (10.3)  54.0   (13.4)
Confused (T score)  64.9c   (16.6)  57.9   (15.2)  51.7  (11.2)
Sad (T score)  63.7   (19.9)  56.0   (18.2)  53.4   (13.2)
Angry (T score)  67.4a  (18.3)  55.1   (13.9)  53.5   (11.3)
Energetic (T score)  46.6   (10.8)  43.6   (10.4)  45.0   (11.4)
Tired (T score)  56.6   (10.1)  54.9   (10.0)  53.7   (11.2)
Happy (T score)  43.0   (12.9)  40.0  (13.6)  42.7   (11.7)
Tense (T score)  59.0   (9.7)  55.0   (12.2)  54.3   (12.8)
Libido status          
% no change  33.3  33.3  58.8
% lower  44.5  47.6  33.8
% higher  22.2  19.1  7.4
Note: ap < 0.05 vs NG and NCG; bp <  0.05 vs NG; cp < 0.01 vs NG. 
Abbreviations: CG, compulsive gamblers; NCG, non-compulsive gamblers; NG, non-gamblers OCD, obsessive-compulsive disorder.Neuropsychiatric Disease and Treatment 2007:3(1) 166
Shapiro et al
administration of the Hamilton Anxiety Scale. “Confusion” is 
a vague term and could indicate cognitive impairment, guilt, 
frustration, disbelief, etc. While our limited survey does not 
reveal why our PD patients are experiencing such emotions, 
screening for these mood states may indicate which patients 
are most likely to experience pathological gambling as a 
result of dopamine agonist medication. However, as these 
are self-report measures, without corresponding objective 
cognitive and emotional measures, the conclusions that can 
be drawn from some of the VAMS items such as “confused” 
and “afraid” are limited.
Other studies have reported that compulsive gamblers 
with PD have noted “never experiencing anything like 
[compulsive gambling] before,” and that such behavior was 
quite unusual for them and could not be explained (Dodd 
et al 2005). However, a higher prevalence of psychiatric/
mood symptoms, in particular anxiety, in problem gamblers 
is to be expected (Petry et al 2005; Pietrzak et al 2005). Previ-
ously, compulsive gambling in PD has been associated with 
an increased sex drive (Dodd et al 2005), and other studies 
have shown that increases in sexually risky behavior may be 
associated with gambling, as both are risk-taking behaviors 
(Martins et al 2004). On the contrary, our study revealed 
that of the ten CG, four reported decreases in libido, and 
only two reported increases. A loss of libido may be an age-
related change.
Admittedly, there are weaknesses to the study. First, as 
the survey was completed on a voluntary basis, the study 
lends itself to underreporting of the actual prevalence of 
compulsive gambling in PD in North Central Florida. Pa-
tients may be unwilling to disclose such private information 
in an impersonal manner. In addition, there may be a geo-
graphical bias in selecting for compulsive gamblers. North 
Central Florida is particularly devoid of casinos or other 
gambling establishments. It has been previously supposed 
that proximity to casinos may contribute to the development 
of compulsive gambling behavior in PD patients (Driver-
Dunkley et al 2003). The prevalence of compulsive gambling 
in this region therefore may underreport the prevalence of 
compulsive gambling in regions with abundant gambling 
facilities. Unfortunately, we cannot verify the accuracy or 
truthfulness with which patients responded to the survey. This 
is an inherent ﬂ  aw in using self-report measures. In addition, 
many patients may not consider their behavior irrational, or 
that they have a gambling “problem.” Such patients may 
not have been truthful with their responses, or may not have 
returned a survey. Furthermore, with the limited number of 
participants who seemingly exhibited compulsive gambling 
behavior (ten), the conclusions that can be drawn from the 
data are equally as limited. The relevance and signiﬁ  cance 
of this study must be evaluated in the context of other cur-
rent and future studies regarding pathological gambling in 
Parkinson’s disease.
Summary
In this survey, we have recognized several characteristics that 
may help identify which PD patients may be the most “at 
risk” for developing compulsive gambling behavior: young 
age, high degree of anxiety and anger, and use of a dopa-
mine agonist. All patients that were suspected of compulsive 
gambling behavior were contacted, informed of the recent 
studies linking compulsive gambling and antiparkinsonian 
medications, and advised to speak to their physician. Future 
goals of this study are to conduct six-month and one-year 
follow-ups on the identiﬁ  ed compulsive gamblers to observe 
if they have sought help for their behavior, and if their 
symptoms become resolved, what interventions were made 
to affect such a change. In the meantime, clinicians should 
be aware of these characteristics associated with pathologi-
cal gambling and be particularly vigilant when treating this 
sub-population of PD.
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